论文部分内容阅读
目的:评价雷贝拉唑与二联疗法联用对幽门螺杆菌(Hp)所致相关性胃炎患者的临床疗效与安全性。方法:选取2015年4月—2016年12月间收治的Hp相关性胃炎患者156例临床资料,按照就诊顺序号将其分为对照组及观察组,每组78例;对照组患者给予雷贝拉唑治疗,观察组患者在对照组基础上加用二联疗法(克拉霉素和左氧氟沙星方案)治疗,评价两组患者用药后的Hp根除情况和安全性以及临床症状的SAS和SDS评分值的变化情况。结果:治疗30 d后,观察组患者Hp根除率为83.33%高于对照组为64.10%(P<0.05),不良反应的发生率为12.82%略低于对照组为14.10%(P>0.05),治疗后临床症状的SAS及SDS评分值显著低于对照组(P<0.05)。结论:采用雷贝拉唑与二联疗法联用治疗Hp所致相关性胃炎患者的临床疗效较好,提高了Hp根除率,且安全性较高。
OBJECTIVE: To evaluate the clinical efficacy and safety of rabeprazole in combination with dual-therapy in patients with gastritis associated with Helicobacter pylori (Hp). Methods: The clinical data of 156 patients with Hp-associated gastritis admitted from April 2015 to December 2016 were selected and divided into control group and observation group according to the sequence number of treatment, 78 cases in each group. The control group was treated with Rebeba In the control group, patients in the observation group were treated with the combination therapy of double-drug (clarithromycin and levofloxacin) to evaluate the eradication and safety of Hp and SAS and SDS scores of the clinical symptoms Changes. Results: After 30 days of treatment, the Hp eradication rate was 83.33% in the observation group and 64.10% in the control group (P <0.05). The incidence of adverse reactions was 12.82%, which was slightly lower than that in the control group (14.10% , SAS and SDS scores of clinical symptoms after treatment were significantly lower than those of the control group (P <0.05). Conclusion: The combination of rabeprazole and two combined therapy for the treatment of Hp-related gastritis in patients with better clinical efficacy, increased Hp eradication rate, and higher safety.